JY 09 - Beijing Dongfang Biotech

Drug Profile

JY 09 - Beijing Dongfang Biotech

Alternative Names: JY09

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator Beijing Dongfang Biotech
  • Class Antihyperglycaemics; Immunoglobulin Fc fragments; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 28 Nov 2016 Beijing Dongfang Biotech plans a phase I trial for Diabetes mellitus (In volunteers) in China (NCT02971722)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top